Improving Treatment Outcomes for Prescription Opioid Dependence
改善处方阿片类药物依赖的治疗结果
基本信息
- 批准号:9104113
- 负责人:
- 金额:$ 57.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-07-15 至 2020-05-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdolescent and Young AdultAdrenergic AgonistsAgonistBuprenorphineCalcium Channel BlockersCessation of lifeChronicConsumptionControlled Clinical TrialsDataDependenceDevelopmentDiseaseDrug InteractionsDrug Metabolic DetoxicationFDA approvedGoalsHealthHeroinHumanIndividualInterviewMaintenanceMediator of activation proteinMethadoneMethodsModelingMorphineMovementN-Type Calcium ChannelsNaltrexoneNarcotic AntagonistsOpiate AddictionOpioidOpioid AnalgesicsOutcomeOutpatientsOverdosePainParticipantPatientsPharmaceutical PreparationsPharmacologic SubstancePhysiologicalPlacebo ControlPlacebosPopulationPostoperative PeriodProceduresPublic HealthRandomizedRegimenRelapseRural CommunitySafetySymptomsTimeTreatment outcomeWithdrawalWithdrawal SymptomWorkaddictionclinical practicecravingfollow-upgabapentinhigh risk behaviorillicit drug useimprovedimproved outcomeinnovationnovelopioid useopioid withdrawalprescription opioidprescription opioid abuseprogramsreverse tolerancesecondary outcomesocial stigmasymptomatologytooltreatment strategy
项目摘要
DESCRIPTION (provided by applicant): Opioid dependence is a serious public health problem, particularly with the dramatic rise in prescription opioid (PO) abuse, but long-term opioid agonist maintenance with methadone or buprenorphine (BUP) may not be optimal for many PO abusers. Yet current opioid detoxification strategies are limited by high relapse rates and/or lack of efficacy in relieving subjective symptoms. In addition, antagonist maintenance with naltrexone (NTX), which may be an optimal longer-term strategy for this population, requires prior opioid detoxification and has been associated with relatively poor outcomes in heroin abusers. This application takes a novel, broad approach to address the problem of PO dependence by determining the 1) utility of adjunct gabapentin (GBP) during outpatient BUP detoxification to improve initial outcomes and 2) feasibility of transitioning PO-dependent patients to depot NTX following detoxification, which may improve longer-term outcomes. GBP, an N-type calcium channel blocker with low abuse potential, potentiates opioid analgesia, decreases both postoperative morphine consumption and movement-related pain, and reverses tolerance to the antinociceptive effects of morphine. GBP is also well tolerated and effective in reducing craving and illicit opioid use in pilot detoxification trials. We propose to assess the efficacy and tolerability of adjunct GBP during BUP-assisted detoxification and the feasibility of subsequent transition to depot NTX therapy in PO-dependent participants. This 8-week, randomized, placebo-controlled clinical trial will determine the potential utility of adjunct GBP i 150 PO- dependent individuals undergoing outpatient BUP detoxification and whether transition to short-term depot NTX therapy is feasible. Our three specific aims are to determine (1) the efficacy and tolerability of GBP to reduce craving and illicit use of opioids in PO-dependent individuals undergoing outpatient BUP detoxification; (2) acceptability and feasibility of transitin to, and short-term maintenance on, depot NTX following detoxification; and (3) prognosticators of completion of the BUP taper, successful induction onto depot NTX, symptomatology, and longer-term outcomes. Currently, the only FDA-approved medications for the treatment of opioid withdrawal are the opioid agonists methadone and BUP, both of which have abuse liability, and NTX, which can produce low levels of withdrawal-like symptoms, especially early in treatment. Our findings, if positive, will support further development of GBP as an adjunct medication as well as provide an integrated, seamless approach to outpatient PO-dependence treatment. Ultimately, this work could impact the addiction field by providing both procedural and pharmacological tools for treating PO dependence that significantly improve outpatient detoxification outcomes and markedly enhance access and transition to NTX therapy. This would shift clinical practice, establishing an effective adjunct regimen for BUP detoxification and
an integrated approach f or transition to NTX therapy. GBP may also be clinically useful for other situations where opioid withdrawal is a concern.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL J MANCINO其他文献
MICHAEL J MANCINO的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL J MANCINO', 18)}}的其他基金
Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
赖右苯丙胺治疗甲基苯丙胺依赖的临床疗效
- 批准号:
8581863 - 财政年份:2013
- 资助金额:
$ 57.29万 - 项目类别:
Clinical Efficacy of Lisdexamfetamine for Methamphetamine Dependence
赖右苯丙胺治疗甲基苯丙胺依赖的临床疗效
- 批准号:
8707413 - 财政年份:2013
- 资助金额:
$ 57.29万 - 项目类别:
AR CAREER DEVELOPMENT COBRE: AMPHETAMINE WITHDRAWAL PARADIGM IN HUMANS
AR 职业发展 COBRE:人类安非他明戒断范例
- 批准号:
8359670 - 财政年份:2011
- 资助金额:
$ 57.29万 - 项目类别:
AR CAREER DEVELOPMENT COBRE: AMPHETAMINE WITHDRAWAL PARADIGM IN HUMANS
AR 职业发展 COBRE:人类安非他明戒断范例
- 批准号:
8168239 - 财政年份:2010
- 资助金额:
$ 57.29万 - 项目类别:
相似海外基金
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The impact of changes in social determinants of health on adolescent and young adult mental health during the COVID-19 pandemic: A longitudinal study of the Asenze cohort in South Africa
COVID-19 大流行期间健康社会决定因素的变化对青少年和年轻人心理健康的影响:南非 Asenze 队列的纵向研究
- 批准号:
10755168 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
A Priority Setting Partnership to Establish a Patient, Caregiver, and Clinician-identified Research Agenda for Adolescent and Young Adult Cancer in Canada
建立优先合作伙伴关系,以建立患者、护理人员和临床医生确定的加拿大青少年和年轻人癌症研究议程
- 批准号:
480840 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Miscellaneous Programs
Incidence and Time on Onset of Cardiovascular Risk Factors and Cardiovascular Disease in Adult Survivors of Adolescent and Young Adult Cancer and Association with Exercise
青少年和青年癌症成年幸存者心血管危险因素和心血管疾病的发病率和时间以及与运动的关系
- 批准号:
10678157 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Fertility experiences among ethnically diverse adolescent and young adult cancer survivors: A population-based study
不同种族青少年和年轻成年癌症幸存者的生育经历:一项基于人群的研究
- 批准号:
10744412 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Treatment development for refractory leukemia using childhood/adolescent, and young adult leukemia biobank
利用儿童/青少年和青年白血病生物库开发难治性白血病的治疗方法
- 批准号:
23K07305 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Molecular design of Two-Way Player CAR-T cells to overcome disease/antigen heterogeneity of childhood, adolescent, and young adult cancers
双向 CAR-T 细胞的分子设计,以克服儿童、青少年和年轻成人癌症的疾病/抗原异质性
- 批准号:
23H02874 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Using Tailored mHealth Strategies to Promote Weight Management among Adolescent and Young Adult Cancer Survivors
使用量身定制的移动健康策略促进青少年和年轻癌症幸存者的体重管理
- 批准号:
10650648 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Developing and Testing a Culturally Tailored Mobile Health and Social MediaPhysical Activity Intervention Among Adolescent and Young Adult ChildhoodCancer Survivors
开发和测试针对青少年和青年儿童癌症幸存者的文化定制移动健康和社交媒体体育活动干预
- 批准号:
10736526 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别:
Pilot Project 1: Creating Bridges to Reproductive Health Care for Rural Adolescent and Young Adult Cancer Survivors
试点项目 1:为农村青少年和青年癌症幸存者搭建生殖保健桥梁
- 批准号:
10762146 - 财政年份:2023
- 资助金额:
$ 57.29万 - 项目类别: